Drug intelligence / Profile preview

SALBUWIN-B

Development stage: Unknown
Lead developer: Medisol Lifescience
Modality: Small Molecules
Administration: Inhalation

Overview

SALBUWIN-B is a combination metered-dose inhaler (MDI) developed and manufactured by Medisol Lifescience. It contains salbutamol, a short-acting beta-2 agonist (SABA), and beclometasone dipropionate, an inhaled corticosteroid (ICS). Salbutamol provides rapid bronchodilation by stimulating beta-2 adrenergic receptors in the airway smooth muscle, while beclometasone reduces airway inflammation by activating glucocorticoid receptors. This combination therapy is indicated for the management of obstructive airway diseases, including asthma and chronic obstructive pulmonary disease (COPD).

Brand names: SALBUWIN-B
Other names: Beclometasone and Salbutamol InhalerBeclometasone + Salbutamol

Targets

GR (Glucocorticoid receptor)ADRB2 (β2)

Beyond the preview

Go deeper on SALBUWIN-B.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SALBUWIN-B.

Explore the full profile